AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

NHS patients risk losing access to the world’s best medicines unless the UK spends more on developing new treatments, the ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of its cancer, heart and kidney ...

AstraZeneca stock bounded into a buy zone Thursday after sales of its cancer drugs beat Wall Street's expectations by about 5 ...

AstraZeneca said work on its new plant north of Charlottesville will begin immediately and be open within five years.

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.

Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...